ANTI WRINKLE INJECTION

Botolin toxin

Botolin toxin injections are an effective and now well-established treatment for lines and wrinkles.

The most commonly treated areas are

  • Crow’s feet lines and wrinkles.
  • Smile lines.
  • Frown lines between the eyebrows.
  • Forehead lines.

This treatment is provided by Dr. Farzana Nazerali in our London clinic.

Product Summary

BOCOUTURE®, botulinum toxin type A, has been available in the U.K. since 2008 as the brand name Xeomin®, which is licenced in the UK for blepharospasm and cervical dystonia. It gained approval for cosmetic use in the UK in July 2010 and is marketed for this indication, with dosing specific to treat glabellar (frown) lines, under the brand name Bocouture®.

Bocouture® claims to be an innovative Botulinum type A formulation, in which the complexing proteins have been removed by an extensive purification process from the botulinum toxin complex. In contrast to the other commercially available preparations, Bocouture® contains the pure 150 kD neurotoxin.

It is widely accepted that the bacterial protein present in other products play a role as promoters of an immune reaction, resulting in a loss of effect and reduction in duration of activity. Studies show that Bocouture®, without the complexing proteins, has the lowest content of protein of all of the available botulinum toxins and furthermore show that repeated application of Bocouture®, even in high doses, does not induce the formation of neutralising anti-bodies.

This means that Bocouture® is able to provide similar results to those achievable with the other products without the risk of antibody formation, providing continual long lasting effects. This could be relevant when large doses are being used for medical indications, but many industry experts question the relevance when this product is used for cosmetic purposes.

Who should not have Bocouture® treatment?

  • Individuals with a known hypersensitivity to any component of the formulation.
  • Patients who have generalised disorders of muscle activity (e.g. myasthenia gravis).
  • Patients where aminoglycoside antibiotics or spectinomycin are already being used or are likely to be used.
  • Patients who have bleeding disorders of any type.
  • Pregnant or lactating women.

Reported side effects include

Bruising or bleeding at the site of injection, headache, and rarely eyelid ptosis or diplopia, and brow droop.

Summary

Procedure Time:

35 minutes (including numbing)

Results:

Immediately

Recovery Time:

7 days for full recovery

Anaesthetic:

Topical cream

Duration Of Results:

2 months – 1 year

Skin test:

None